Literature DB >> 15570889

Neurotoxic morphological changes induced in the medial prefrontal cortex of rats behaviorally sensitized to methamphetamine.

Tomoko Kadota1, Ken Kadota.   

Abstract

The present study examined whether the development in rats of behavioral sensitization to methamphetamine (MAP) is related to the development of neurotoxic morphological changes presumably induced in the medial prefrontal cortex (MFC). Male rats were intraperitonieally injected with MAP (5 mg/kg) once a day for 12 days (day 1-day 12), and then the drug was withdrawn for 7-42 days (WD7-WD42). The MAP- treatment caused hypersensitivity of a successive head-movement stereotypy, which reached a basic plateau level on day 4, and rose successively to a higher level by day 12. Morphological changes were histochemically and morphometrically examined in the MFC. In the strata covering layers II and III, the densities of tyrosine hydroxylase (TH)-immunoreactive axons decreased on a daily basis to 50% of the control on day 4 and then to 40% on days 6 and 12. The densities of dopamine-,beta-hydroxylase (DBH)-immunoreactive axons did not change during the injection period. A few TUNEL-positive cells were observed in a unit area (0.25 mm2) covering layers II-V on day 6 and they increased to 19 and 16 on day 12 and WD7, respectively. These observations demonstrate a role for the neurotoxic changes in the MFC in the processes of behavioral sensitization of a stereotypy to a low dose of MAP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570889     DOI: 10.1679/aohc.67.241

Source DB:  PubMed          Journal:  Arch Histol Cytol        ISSN: 0914-9465


  13 in total

Review 1.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

2.  Methamphetamine affects cell proliferation in the medial prefrontal cortex: a new niche for toxicity.

Authors:  Airee Kim; Chitra D Mandyam
Journal:  Pharmacol Biochem Behav       Date:  2014-09-28       Impact factor: 3.533

3.  Developmental GABAergic deficit enhances methamphetamine-induced apoptosis.

Authors:  Tomohiro Abekawa; Koki Ito; Yasuya Nakato; Tsukasa Koyama
Journal:  Psychopharmacology (Berl)       Date:  2011-04-14       Impact factor: 4.530

4.  Activation of Trace Amine-Associated Receptor 1 Stimulates an Antiapoptotic Signal Cascade via Extracellular Signal-Regulated Kinase 1/2.

Authors:  Xiao Shi; Tracy L Swanson; Nicholas B Miner; Amy J Eshleman; Aaron Janowsky
Journal:  Mol Pharmacol       Date:  2019-08-13       Impact factor: 4.436

5.  Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction.

Authors:  Kevin C Lord; Sylvia K Shenouda; Elizabeth McIlwain; Dimitrios Charalampidis; Pamela A Lucchesi; Kurt J Varner
Journal:  Cardiovasc Res       Date:  2010-02-05       Impact factor: 10.787

Review 6.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

Review 7.  Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  Laura E Halpin; Stuart A Collins; Bryan K Yamamoto
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

8.  Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis.

Authors:  Chitra D Mandyam; Sunmee Wee; Amelia J Eisch; Heather N Richardson; George F Koob
Journal:  J Neurosci       Date:  2007-10-17       Impact factor: 6.167

9.  Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment.

Authors:  M P Mosti; G Flemmen; J Hoff; A K Stunes; U Syversen; E Wang
Journal:  Osteoporos Int       Date:  2015-10-26       Impact factor: 4.507

Review 10.  Bidirectional causality between addiction and cognitive deficits.

Authors:  Patrick R Melugin; Suzanne O Nolan; Cody A Siciliano
Journal:  Int Rev Neurobiol       Date:  2020-12-30       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.